PrEP

(Pre-exposure prophylaxis)

Christianne Madriaga,
Johanna Sotelo, Enass
Ramadan,
& Annet N. Jones
GNRS 587
WHO are we teaching?

For provider education as requested by Health Educator

at Ontario Health Center. PrEP delivered in a poster
format. Poster set-up in conference room for providers
to read and have as a reference tool .
WHAT is PrEP?
PrEP stands for Preexposure Prophylaxis and is used to reduce the
contraction of HIV in high risk individuals. These individuals are
screened and accessed through CDC criteria to determine if PrEP
is beneficial. Turvada is a combination pill composed of Viread and
Emtriva currently prescribed for PrEP use.

Truvada was approved by FDA for use as PrEP in July 2012.

 WHY is PrEP Needed?
PrEP is needed by people who are at HIGH RISK for acquiring
HIV, such as injection drug users, MSM, sex workers or
anyone with multiple sex partners.
Daily PrEP reduces the risk for getting HIV from Sex by more
than 90%.
Risk of getting HIV from sex can even be lower if you combine
PrEP with condoms and other preventions.
Among people who inject drugs, it reduces the risk by more
than 70%
(CDC, 2014)
 WHY is PrEP Needed?
Approximately 50,000 people in the United States are infected with HIV
each year.

From 2008 through 2010, HIV incidence remained stable or declined

among IDU and heterosexuals of all races

However,incidence increased among MSM (12% increase), especially

among adolescent and young adult MSM (aged 13-24 years) (22%
increase) .

The greatest number of new HIV infections among MSM occurred in

young African American MSM (4,800).
(CDC, 2014)
 Why Continued.?

In 2010, 63% of the estimated 47,500 new infections were attributed

to male-male sexual activity without injection drug use, 4% to male-
male sexual activity with injection drug use, 25% to male-female
sexual contact without injection drug use, and 8% to injection drug
use.

Among the 25% of persons newly infected through heterosexual

activity, 66% were African American women and men.

(CDC, 2014)
Cost of HIV Treatment

Unfortunately, this number is

increasing every year.

(Wegner, 2014)
(CDC, 2016)
HOW is PrEP used?
HIV (-) person takes PrEP to have high levels in their
bloodstream before HIV exposure.

PrEP stop the virus from entering cells and replicating.

It prevents HIV from manifesting itself and the person remains

HIV negative.

(PrEP) is a course of HIV drugs taken daily before exposure

PrEp is taken for periods when a person may be at risk of HIV

infection.
(CDC, 2014)
Men Who Have Sex
With Men

Brief Questions asked to assess for key

sexual practices associated with risk of HIV
acquisition

(CDC, 2014)
Heterosexual Men
and Women

Brief Questions asked to assess for key

sexual practices associated with risk of HIV
acquisition

(CDC, 2014)
Injection Drug Use
Be alert to signs and symptoms
of illicit drug use

Behavior and medication

assisted or inpatient drug
treatments

Assess for relapse

Referral for drug treatment,

mental health and social
services
(CDC, 2014)
Medication Adherence

Critical to achieving the

maximum prevention
benefit and reducing the
risk of selecting for a drug-
resistant virus if non-
adherence leads to HIV
acquisition.

CAUTION: PrEP does not

prevent other STIs

(CDC, 2014)
Poster for Clinic
References
Center for Disease Control and Prevention. (2014). US public health service: Preexposure prophylaxis for the
prevention of HIV infection in the United States: A clinical practice guideline. Atlanta, GA: Department of Health
and Human Services. Retrieved from https://www.cdc.gov/hiv/risk/prep/index.html

Center for Disease Control and Prevention. (2016). HIV prevention modeling study. Retrieved from
https://www.cdc.gov/nchhstp/newsroom/2016/croi-press-release-prevention.html

Fox, I. (2015, June 30). Nursing 101: All about breastfeeding. Retrieved November 09, 2017, from
http://www.parents.com/baby/breastfeeding/basics/nursing-101-all-about-breastfeeding/

Petroll, A., Walsh, J., Owczarzak, J., McAuliffe, T., Bogart, L., & Kelly, J. (2017). PrEP awareness, familiarity,
comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS & Behavior,
21(5), 1256-1267. doi:10.1007/s10461-016-1625-1

Rowniak, S., Ong-Flaherty, C., Selix, N., & Kowell, N. (2017). Attitudes, beliefs, and barriers to PrEP among
trans men. AIDS Education & Prevention, 29(4), 302-314. doi:10.1521/aeap.2017.29.4.302

Wenger, A. (2014, December 16). The cost of treating HIV: One mans monthly medical bill. Retrieved
November 13, 2017, from https://www.healthline.com/health/hiv-aids/monthly-cost-treating-hiv#1